In addition to her role as Chief Executive Officer, Veronica is also a member of the Board of Directors of LimmaTech. In 2009, she joined GlycoVaxyn AG as head of the clinical and regulatory affairs department and was Executive Director at the time of the company’s acquisition by GlaxoSmithKline plc in February 2015. During her 6 years at the firm, Veronica held different positions, from leading the clinical and regulatory department to taking care of business development of the company. Before joining GlycoVaxyn, she held leading roles focused on clinical R&D and international regulatory affairs in medical technology and biotechnology companies, including EndoArt SA and Allergan Inc. Veronica holds an engineering degree from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and a PhD in life sciences in the field of cardiovascular biomedical engineering from the Swiss Federal Institute of Technology, Lausanne (EPFL).
As Vice President Business and IP Strategy, Michael is responsible for LimmaTech’s business development activities and also manages the intellectual property strategy. Previously, Michael was VP Research and IP and led the company’s development of vaccine candidates through their early stages. He started co-inventing a platform technology for protein glycosylation during his postdoc at university that he then continued to develop while working in leading positions in GlycoVaxyn AG. Based on this platform asset, the company was acquired by GlaxoSmithKline plc in February 2015. Michael has a PhD in Biochemistry from the Swiss Federal Institute of Technology, Zurich (ETH Zurich). He has authored several peer-reviewed publications, has managed and acquired multiple non-dilutive funds and is an inventor of several granted patents establishing the scientific framework of the bioconjugation technology.
As Chief Operations Officer, Dominique is responsible for the alignment of the company’s operations with its goals and strategy. In addition, he leads the Process and Analytical development department, which is in charge of developing cGMP and industry compliant manufacturing processes, clinical trial material (CTM), analytical methods for scale-up. In his function as a Swiss Responsible Person, he is also responsible for GDP compliant import and distribution of CTM to the trial sites, in particular in Switzerland. Dominique joined GlycoVaxyn AG in 2011 as Head of Process Development and Industrialization and held that position at the time of the company’s acquisition by GlaxoSmithKline plc in February 2015. Before this, he acquired significant experience in cGMP quality control, manufacturing and validation while working for more than 5 years at Cytos Biotechnology AG. Dominique holds a PhD in science from the University of Zurich and studied Adenovirus biology and its application in tumor therapy.
As Chief Scientific Officer, Amir is responsible for the research and discovery activities of the company and sets the scientific direction and priorities. He leads the development of early stage vaccine and therapeutic research projects as well as novel platform development. Previously, Amir was Head of Discovery and a member of the management team at GlycoVaxyn AG at the time of its acquisition by GlaxoSmithKline plc in February 2015. With 10 years’ experience in glycobiology, he established the Discovery department of GlycoVaxyn in 2013 where he was responsible for the development of proprietary research projects and platforms. Amir obtained his PhD in 2005 from the University of British Columbia, Canada, followed by a Post-Doctoral Fellowship at Alberta Glycomic Center, University of Alberta. He is the author of several peer-reviewed articles and an inventor of several granted patents.
As Vice President Clinical and Regulatory Affairs, Patricia is responsible for LimmaTech’s vaccine and therapeutic clinical programs. She joined GlycoVaxyn in 2014 in the Clinical Department and became part of LimmaTech’s Executive Management team in 2019. Prior to GlycoVaxyn, Patricia held various roles in clinical research in several biotech companies and CROs. In her over 8 years of industrial experience, she has acquired significant expertise in diverse vaccine and therapeutic clinical indications and has overseen studies ranging from Phase I to Phase IV. Patricia has a degree in Biochemistry from the National University of Cordoba, Argentina. After relocating to Switzerland, she received her PhD in Natural Science from the University of Zürich in 2010.
As CFO, Paul is responsible for finance, administration, IT and human resources at LimmaTech. Most recently, he was CFO of GlycoVaxyn AG at the time of its acquisition by GlaxoSmithKline plc in February 2015. Previously, Paul was the Chief Financial Officer of Source Capital AG, a FINMA-regulated algorithmic trading firm in Switzerland from 2012 to 2014. He was Managing Director of Investors Guaranty, a boutique private equity and venture capital firm, where he managed the financial and corporate development activities and served as a board member for the group’s portfolio companies from 2001 to 2012. Prior to 2001, he worked for SEI Investments Inc. in the United States and Switzerland in various corporate finance positions focusing on the company’s new ventures. Paul holds a B.S. in finance from LaSalle University in Philadelphia and an MBA from Villanova University in Pennsylvania (USA).